Advanced Biomedical Technologies Inc (ABMT) financial statements (2020 and earlier)

Company profile

Business Address 350 FIFTH AVE., 59TH FLOOR
NEW YORK, NY 10118
State of Incorp. NV
Fiscal Year End October 31
SIC 3842 - Orthopedic, Prosthetic, and Surgical Appliances and Supplies (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

10/31/2019
10/31/2018
10/31/2017
10/31/2016
10/31/2015
10/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments67773874
Cash and cash equivalents67773874
Inventory, net of allowances, customer advances and progress billings64   3 
Inventory64   3 
Prepaid expense  17201819
Other undisclosed current assets5033    
Total current assets:1194025275993
Noncurrent Assets
Property, plant and equipment991036172107108
Other undisclosed noncurrent assets   1 16
Total noncurrent assets:991036174107124
TOTAL ASSETS:21914285101166218
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities     106
Accounts payable     1
Accrued liabilities     105
Due to related parties4,9174,3263,7673,0843,5282,989
Other liabilities 44340933897106
Other undisclosed current liabilities1,7809939041,0421,002756
Total current liabilities:6,6975,7615,0804,4634,6273,956
Noncurrent Liabilities
Total liabilities:6,6975,7615,0804,4634,6273,956
Commitments and contingencies   1  
Stockholders' equity
Stockholders' equity attributable to parent(6,478)(5,619)(4,995)(4,362)(4,461)(3,739)
Common stock111111
Additional paid in capital2,7682,7402,6742,5211,9491,928
Accumulated other comprehensive income (loss)33427310104(148)(267)
Accumulated deficit(9,581)(8,633)(7,679)(6,988)(6,263)(5,400)
Total stockholders' equity:(6,478)(5,619)(4,995)(4,362)(4,461)(3,739)
Other undisclosed liabilities and equity   (1)  
TOTAL LIABILITIES AND EQUITY:21914285101166218

Income statement (P&L) ($ in thousands)

10/31/2019
10/31/2018
10/31/2017
10/31/2016
10/31/2015
10/31/2014
Revenues12     
Cost of revenue(8)     
Gross profit:4     
Operating expenses(609)(634)(404)(461)(605)(618)
Other operating expense, net    (258)(210)
Other undisclosed operating income    258 
Operating loss:(605)(634)(404)(461)(605)(828)
Nonoperating income (expense)(344)(19)(30)(14)(16)0
Investment income, nonoperating000000
Other nonoperating expense(18)(19)(30)(14)(16) 
Interest and debt expense(13)(14)(16)(249)(241)(181)
Loss from continuing operations before equity method investments, income taxes:(962)(667)(449)(725)(863)(1,009)
Other undisclosed income (loss) from continuing operations before income taxes13(287)(242)   
Loss before gain (loss) on sale of properties:(949)(953)(692)(725)(863)(1,009)
Other undisclosed net income     181
Net loss available to common stockholders, diluted:(949)(953)(692)(725)(863)(828)

Comprehensive Income ($ in thousands)

10/31/2019
10/31/2018
10/31/2017
10/31/2016
10/31/2015
10/31/2014
Net loss:(949)(953)(692)(725)(863)(828)
Other comprehensive income (loss)62263(94)252119 
Comprehensive loss:(887)(691)(786)(472)(744)(828)
Other undisclosed comprehensive income, net of tax, attributable to parent     4
Comprehensive loss, net of tax, attributable to parent:(887)(691)(786)(472)(744)(824)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: